Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

Key Patent Granted For AAVLife’s Gene-Therapy Program to Treat Cardiomyopathy in Friedreich’s Ataxia


"As this recently issued patent indicates, AAVLife is building strong intellectual-property protection at the same time we are steadily progressing our R&D toward an urgently needed therapy,” said Amber Salzman, Chief Executive Officer of AAVLife.

Read More:  Key Patent Granted for AAVLife's Gene-Therapy Program to Treat Cardiomyopathy in Friedreich's ataxia

About the Author

Jen Farmer

Jen Farmer

Chief Executive Officer


Event I.jpg


Archived in
  Scientific News



Tagged in
FARA Scientific News

Site Map     Privacy Policy     Service Terms     Log-in     Contact     Charity Navigator